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Abstract
The aim of this study was to use a multimodal molecular imaging approach to serially assess regional metabolic changes in the
knee in an in vivo anterior cruciate ligament transection (ACLT) canine model of osteoarthritis (OA). Five canine underwent
ACLT in one knee and the contralateral knee served as uninjured control. Prior, 3, 6, and 12 weeks post-ACLT, the dogs
underwent 18F-fluoro-D-glucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) and magnetic
resonance imaging (MRI). The MRI was coregistered with the PET/CT, and 3-dimensional regions of interest (ROIs) were
traced manually and maximum standardized uptake values (SUVmax) were evaluated.
18F-fluoro-D-glucose SUVmax in the ACLT
knee ROIs was significantly higher compared to the uninjured contralateral knees at 3, 6, and 12 weeks. Higher 18F-FDG
uptake observed in ACLT knees compared to the uninjured knees reflects greater metabolic changes in the injured knees
over time. Knee 18F-FDG uptake in an in vivo ACLT canine model using combined PET/CT and MRI demonstrated to be highly
sensitive in the detection of metabolic alterations in osseous and nonosteochondral structures comprising the knee joint.
18F-fluoro-D-glucose appeared to be a capable potential imaging biomarker for early human knee OA diagnosis, prognosis,
and management.
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Introduction
Knee osteoarthritis (OA) is a common and debilitating dis-
ease that affects 27 million people in the United States.1
Health-care expenditures of this condition have been
estimated at US$186 billion annually.2 The increasing impor-
tance of imaging OA for diagnosis, prognosis, and follow-up
is well acknowledged. Although conventional radiography is
the gold standard imaging technique for the evaluation of OA
in clinical practice and in clinical trials, more sensitive ima-
ging modalities are needed for the earlier diagnosis of OA. It
is now widely agreed that OA is a disease of the whole joint.
Magnetic resonance imaging (MRI) can assess all morpholo-
gical structures of the joint, including cartilage, meniscus,
ligaments, muscle, subarticular bone marrow, and synovium
and thus can visualize the knee as a whole organ in 3 dimen-
sions.3 A comprehensive MR examination of the joint struc-
tures requires multiple sequences2 and thus requires longer
acquisition times. The MRI contrast agents such as ionic
gadolinium chelates can be used to further evaluate cartilage
composition (Delayed gadolinium enhanced Magnetic Reso-
nance Imaging of cartilage [dGEMRIC]). Furthermore, it can
detect microcirculation by dynamic contrast-enhanced MRI;
however, these techniques increase the scan time and
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complexity3 and fail to assess cell metabolism. Nuclear med-
icine and specifically positron emission tomography (PET)/
computed tomography (CT) procedures using 18F-fluoro-D-
glucose (18F-FDG) have been utilized to demonstrate meta-
bolic changes in knee tissues, inflammation, and prosthesis
infection.4 Positron emission tomography/CT enables a
pathophysiologic imaging and can provide different and
complementary information than MRI. Increasingly, it can
also be obtained at low radiotracer doses, thus reducing the
ionizing radiation dose.3 Although 18F-FDG as a metabolic
tracer is currently primarily used for oncologic diagnosis,
therapy monitoring, and research, it has great potential for
molecular musculoskeletal imaging.4-7 The 18F-fluoro-D-glu-
cose PET can evaluate synovitis and bone marrow lesions
associated with OA.8 The 18F-fluoro-D-glucose as a glucose
analog cannot be further metabolized after phosphorylation
and is trapped and accumulates within cells. This offers the
opportunity to quantify 18F-FDG PET uptake at sites of
pathological increased glucose metabolism also in the
musculoskeletal tissue. Glucose metabolism is affected by
pro-inflammatory tumor necrosis factor a and increases in
inflamed tissue,9 making PET also a capable molecular ima-
ging technique for the detection and quantification of inflam-
mation.10-12 Surgically induced OA has been used in animal
models to study the pathogenesis of posttraumatic OA
(PTOA). Dogs are the most widely used large animal model
for translational research in OA compared to smaller species
where macro- and microscopic anatomy, cartilage composi-
tion, and matrix turnover may significantly differ from that of
humans.13 The most commonly surgically created model
used is the anterior cruciate ligament transection (ACLT).
The results are highly reproducible and develop
promptly.13,14 The rationale for utilizing this model is that
anterior cruciate ligament (ACL) injury causes joint destabi-
lization, which subsequently leads to PTOA. In a mouse
study using 18F-FDG, Irmler et al showed a correlation of
18F-FDG PET/CT uptake and histopathological evaluation of
inflammatory experimental arthritis.12 Paquet et al and Ume-
moto et al showed that 18F-FDG uptake increased with the
progression of arthritis in a rat arthritis model.15,16 The
18F-FDG PET has also proven its usefulness in diagnosing
inflammation and infection in patients with painful hip and
knee arthroplasties as well as rheumatoid arthritis.17,18
Recently, 18F-FDG PET uptake has been associated with age
and OA.19-21
The advantages of 18F-FDG PET/CT over conventional
nuclear medicine techniques to assess inflammation and
infection include higher sensitivity and better resolution
images, improved target-to-background ratio, and faster scan
times.4,10 Moreover, heightened interest in the use of cross-
sectional imaging techniques and their multimodal combina-
tion in clinical practice has led to combined hybrid modalities
such as PET/CT and PET/MRI, largely because intraindivi-
dual comparative studies on the usefulness of combining
functional and morphologic imaging for patients with OA
have been lacking.
As far as we know, there is no published literature with
regard to serial coregistered molecular imaging of both
18F-FDG PET/CT and MRI in an in vivo canine model of
OA. The aim of this study was to serially assess the metabolic
activity in the knee, including both osseous and nonosteochon-
dral structures, using a combination of 2 imaging modalities
18F-FDG PET/CT and MRI in an in vivo ACLT canine model
of OA. We hypothesized that the knees that underwent ACLT
would show greater 18F-FDG uptake than the uninjured knees.
Materials and Methods
Study Design
Procedures were approved by the local University Institutional
Laboratory Animal Care and Use Committee. Five (n ¼ 5)
healthy, skeletally mature male beagles (age 5 years; weighing
10-13 kg) were used. All dogs were without any clinical and
radiological signs of orthopedic disorders. The dogs were indi-
vidually housed in indoor pens and were fed a standard diet
with water ad libitum.
Induction of OA
Dogs underwent general anesthesia induced by acepromazine
(intravenously (IV), 0.2 mg/kg; Vedco, Saint Joseph, Missouri),
ketamine (IV, 6 mg/kg, Ketaset; Fort Dodge Animal Health,
Overland Park, Kansas), and diazepam (IV, 0.35 mg/kg, Valium;
Roche, Madison, Wisconsin) and maintained by isoflurane (Iso-
Flo; Abbott, Parsippany, New Jersey; infusion, 2%-4%). Bilat-
eral knee arthroscopy utilizing standard portals was performed to
evaluate intra-articular structures. Using randomization, one
knee had the ACL transected, while the ACL in the contralateral
knee was left intact (uninjured). The contralateral knee arthro-
scopy was performed to evaluate knee structures and to balance
possible effects of the arthroscopy procedure itself, such as swel-
ling or effusion, on postoperative knee imaging.
Magnetic Resonance Imaging
Prior, 3, 6, and 12 weeks after ACLT, under general anesthe-
sia, the canines underwent MRI. The MRI was performed
using a 3-T MRI human whole-body system (Achieva; Philips
Healthcare, Cleveland, Ohio) using an 8-channel knee coil.
Dogs were placed in the supine position, with both knees
extended in the knee coil. A custom-made table was used to
ensure the same position in both the MRI and the PET/CT
imaging. A clinical standard transaxial proton density (PD)
turbo spin-echo (TSE) Spectral Presaturation with Inversion
Recovery (SPIR) sequence was used (Echo time [TE] ¼ 15
milliseconds, repetition time [TR] ¼ 2100 milliseconds, flip
angle 90, slice thickness ¼ 2 mm, field of view (FOV) ¼ 115
mm, acquisition matrix: 144  124, voxel size: Foot-to-Head
[FH] 0.56 mm, Anterior-to-Posterior [AP] 0.7 mm), followed
by a sagittal PD TSE fat-saturated sequence (TE ¼ 45 milli-
seconds, TR ¼ 2200 milliseconds, flip angle: 90, slice thick-
ness: 2 mm, FOV ¼ 88 mm; Figures 1 and 2).
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Positron Emission Tomography/CT Imaging
Prior, 3, 6, and 12 weeks after ACLT, under general anesthe-
sia, the dogs underwent 18F-FDG PET/CT. Dogs fasted 6
hours prior to scan. They were kept in transport cages 4 hours
prior to scan to limit physical activity. The participants were
placed in the supine position in the custom-made table with
both knees extended in the designed custom-made foam knee
coil in order to mimic the same position as in the MRI knee
coil and facilitate MRI coregistration. The table and foam
knee coil together further helped to consistently coregister
both modalities. Glucose levels were measured before 111
MBq (3 mCi) of 18F-FDG was injected in the cephalic vein
via IV catheter. The list mode time-of-flight raw data was
acquired on the Gemini 64 TF with Astonish (Philips, Cleve-
land, Ohio) PET/CT system. Four millimeter isotropic voxel
data sets (144  144 matrix size using a 576 mm FOV) and
90 seconds/bed were used. Images were reconstructed using
the system default reconstruction parameters with the 4 mm
voxel reconstruction (33 subsets and 3 iterations). Computed
tomography was acquired using the multislice system at 120
KVp, 163 mAs and reconstructed with a 4-mm slice thickness
(512  512 matrix size using 600 mm FOV) for attenuation
correction and coregistration. Whole-body PET was acquired
30 minutes after 18F-FDG administration for a duration of 20
minutes (Figures 1-3).
Positron Emission Tomography/MRI Analysis
The MRI and the PET/CT scans were performed in the same
week for each time point. They were coregistered using the
Philips IntelliSpace Portal workstation that uses an interpola-
tion methodology to adjust for different matrix sizes. Three-
dimensional (3-D) regions of interest (ROIs) were traced
manually by one author (M.I.M.) to determine the SUVmax in
a consistent way. Six-millimeter-diameter 3-D spheres were
traced for the lateral femoral condyle, medial femoral condyle,
lateral tibia, and medial tibia. Four-millimeter 3-D spheres
were traced for the lateral meniscus and medial meniscus and
3-mm 3-D spheres were traced for the ACL and posterior cruci-
ate ligament (PCL; Figure 2).
Statistical Analyses
The linear mixed-effect model was used to study the associa-
tion between the type of treatment (ACLT and uninjured) and
the SUVmax at each ROI and time point of the PET images, as
well as the association of the SUVmax among the time points at
Figure 1. Representative knee PET/MR coregistered, MRI and 18F-FDG PET (from left to right) transaxial views at baseline (top row), showing
detailed knee morphology (ACL delineated in black dotted ellipse) and low 18F-FDG uptake compared to 3 weeks post-ACLT (bottom row)
showing higher 18F-FDG uptake within the knee joint. At baseline, 18F-FDG PET alone showed background uptake, making knee structure
assessment challenging. ACLT indicates anterior cruciate ligament transection; 18F-FDG, 18F-fluoro-D-glucose; MRI, magnetic resonance imaging;
PET, positron emission tomography.
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each ROI for ACLT and uninjured, respectively. In addition, to
determine correlation within and between dogs, the
Holm-Bonferroni method was used to adjust for multiplicity.
P values < .05 were considered statistically significant. Statis-
tical analysis was performed using SAS v. 9.3 (SAS Institute,
Cary, North Carolina).
Results
Magnetic resonance imaging and 18F-FDG PET/CT scans were
successfully completed prior, 3, 6, and 12 weeks after ACLT
for all dogs, and all the image sets were successfully coregis-
tered (Figures 1 and 2).
All the ROIs assessed in the ACLT knees compared to the
uninjured knees presented with significantly higher FDG
uptake quantified by SUVmax at 3, 6, and 12 weeks (Figures
1-3; Table 1) including the lateral and medial femoral con-
dyles, tibia, menisci, and PCL.
Comparing the FDG uptake in the different regions of the
ACLT knees at 3, 6, and 12 weeks to baseline revealed sig-
nificantly higher SUVmax values also in the lateral and medial
femoral condyles, lateral tibia, medial meniscus, and PCL
(Figures 1-4; Table 2). For the medial tibia and lateral
meniscus, an elevated SUVmax compared to baseline was
found only at the later postinjury time points at 6 and 12
(Figure 4; Table 2).
Interestingly, the FDG uptake was elevated above baseline
in all assessed regions (ROIs of bone, menisci, and PCL) in the
ACLT knees at 12 weeks. On the other side, in the uninjured
knees, FDG uptake returned to baseline levels at 12 weeks
(Figure 4).
In the uninjured knees, the metabolic uptake in the lateral
femoral condyle at 3 weeks was significantly higher relative to
the later follow-up time points at 6 and 12 weeks. Also, the
lateral meniscus presented significantly higher FDG uptake at 3
weeks compared to 6 and 12 weeks. The ACL at 3 weeks
presented more intense FDG update (quantified by SUVmax)
than at 12 weeks. The other regions presented elevated SUVmax
at 3 weeks relative to baseline, 6, and 12 weeks but were not
statistically significantly different after adjusting for multiple
comparisons (Figure 4; Table 2).
Discussion
Our findings demonstrate the feasibility of multimodal mole-
cular imaging using 18F-FDG PET/CT coregistered with MRI
Figure 2. Representative 18F-FDG PET (top) and 18F-FDG PET/MRI coregistration (bottom) axial, sagittal, and dorsal views (from left to right) 3
weeks after ACLT. Showing the medial femoral condyle 3-D ROI (yellow circle) in the PET/MRI coregistered views, allowing for precise
anatomic localization compared to the 18F-FDG PET alone. ACLT indicates anterior cruciate ligament transection; 18F-FDG, 18F-fluoro-D-
glucose; MRI, magnetic resonance imaging; PET, positron emission tomography.
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in the knee to serially assess and quantify metabolic changes in
bone and nonosteochondral structures of the knee in a surgi-
cally induced (ACLT) canine model of OA.
At 3, 6, and 12 weeks, each assessed region in the ACLT
knees had greater 18F-FDG uptake than the uninjured knees.
This finding is reflecting greater metabolic changes in the
injured knees overtime relative to the uninjured knees due
to the instability created by the ACL transection. The results
are consistent with a similar study in patients with knee OA
where the investigators also found higher metabolic uptake in
whole joint ROIs in OA knees compared to uninjured knees.21
The same study found 18F-FDG uptake in the PCL and sub-
chondral lesions in the OA knees that correlated with bone
edema on the MRI. These results are consistent with a
reported rat study where 18F-FDG accumulation in
arthritis reflected proliferating pannus and inflammatory
activity enhanced by inflammatory cytokines, suggesting
that 18F-FDG mPET was effective for quantifying the
inflammatory activity of arthritis and/or its therapeutic
response.15 Moreover, 18F-FDG PET uptake has been corre-
lated with OA coupled with age and gender.19,20
18F-fluoro-D-glucose in ACLT knees did not return to base-
line at 12 weeks due to the joint damage produced by ACL
transection and the consequent OA initiation. Interestingly, the
uninjured contralateral knees also presented elevated 18F-FDG
uptake at 3 weeks, returning to baseline levels at 6 and 12
weeks. This may be related to gait alterations due to joint
instability induced by transecting the ACL, therefore shifting
the dog’s weight to the uninjured knee.
We chose arthroscopic surgery to deliver joint insults so as
to minimize profound effects of arthrotomy on the joint,
which may lead to substantial synovitis, hemorrhage, joint
capsular fibrosis, and the associated pain and dysfunction.
The dog is one of the most common studied species with
respect to models of OA along with rabbits and rodents. Most
importantly, clinical knee OA does occur in dogs due to
Figure 3. Representative whole-body 18F-FDG PET at baseline (A) and 3 weeks (dorsal and sagittal views, respectively (B and C) after ACLT.
Red circles show increased 18F-FDG uptake in the ACLT knee in comparison with the contralateral uninjured knee. ACLT indicates anterior
cruciate ligament transection; 18F-FDG, 18F-fluoro-D-glucose; PET, positron emission tomography.
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similar causes and results in similar signs and symptoms as is
seen in humans.
Adding the MR coregistration enhances remarkably the
ability to match anatomical structures to the metabolic PET
maps. This is of paramount importance when assessing non-
osteochondral structures, such as meniscus or ligaments. We
utilized MRI in this study to advance the visualization and to
accurately improve the localization of nonosteochondral knee
tissues that otherwise could not have been delineated using
PET/CT alone. The combination of these imaging modalities
allowed precise assessment of different regions in the knee.
In previous studies, 18F-FDG uptake was assessed using the
whole knee as 1 region21 or only 2 regions segregating bone
and soft tissue.20 The authors were not able to evaluate dif-
ferent knee regions due to the inability to discriminate joint
structures. The present study allowed us to delineate and
assess precisely 3-D ROIs within the knee joint, including
menisci and ligaments. As a result, we successfully were able
to assess morphology in conjunction with quantitative meta-
bolic activity.
The resolution provided by the PET/CT coregistration,
which performs interpolation for matrix upscaling, was
acceptable for this canine animal model. Due to the size of
the dog knee, the 3-D ROIs applied (6, 4, and 3 mm) fall in
the range of the PET voxel size used, which is a limitation.
Our team is currently developing smaller voxel reconstruc-
tion methodologies (high-definition PET) that will facilitate
more precise assessments in the future. Therefore, combined
PET/CT and MR using 18F-FDG as a tracer is a capable and
detailed tool to quantify experimental joint metabolic
changes accurately and noninvasively in vivo, as we demon-
strated in this study.
Limitations of the study design have to be noted. We used
the contralateral knee joint as the uninjured group instead of
using control, nonoperated dogs. This minimized interanimal
variation. The inclusion of control nonoperated dogs could
provide additional insights into joint metabolic changes due
to possibly altered limb loading patterns after ACLT in the
contralateral joint. The study finalized 12 weeks after ACLT
and thus does not give insight into even longer longitudinal
changes. Further studies are needed with a larger dog popula-
tion to elucidate the different joint metabolic changes that we
observed in the ACLT and uninjured knees. Additionally,
18F-FDG dose reduction and optimization should be considered
Table 1. 18F-FDG Maximum Standardized Uptake Values (SUVmax) of 3-D Regions of Interest (ROIs) in the ACLT and the Uninjured Knee at
Baseline, 3, 6, and 12 Weeks Post-ACLT.a
Assessed ROI Timeline ACLT SUVmax Estimates (Mean + SE) Uninjured Estimates (Mean + SE) Linear Mixed Model P Value
Lateral femur Baseline 0.47+ 0.1 0.51+ 0.07 .54
3 weeks 2.52+ 0.67 1.12+ 0.25 .033a
6 weeks 1.23+ 0.08 0.46+ 0.05 <.001a
12 weeks 1.44+ 0.15 0.48+ 0.05 <.001a
Medial femur Baseline 0.44+ 0.07 0.39+ 0.06 .06
3 weeks 2.54+ 0.63 0.99+ 0.26 .009a
6 weeks 1.29+ 0.1 0.45+ 0.05 <.001a
12 weeks 1.3+ 0.09 0.43+ 0.05 <.001a
Lateral tibia Baseline 0.41+ 0.06 0.43+ 0.03 .66
3 weeks 2.42+ 0.66 1.13+ 0.33 .01a
6 weeks 0.77+ 0.07 0.36+ 0.07 <.001a
12 weeks 0.94+ 0.12 0.47+ 0.04 .007a
Medial tibia Baseline 0.32+ 0.04 0.35+ 0.04 .26
3 weeks 3.06+ 1.03 1.07+ 0.39 .033a
6 weeks 0.1+ 0.11 0.41+ 0.05 .004a
12 weeks 1.14+ 0.11 0.36+ 0.03 <.001a
Lateral meniscus Baseline 0.43+ 0.05 0.47+ 0.04 .13
3 weeks 2.28+ 0.41 1.07+ 0.23 .001a
6 weeks 1.12+ 0.07 0.42+ 0.06 <.001a
12 weeks 1.33+ 0.12 0.47+ 0.06 <.001a
Medial meniscus Baseline 0.32+ 0.03 0.4+ 0.04 .008a
3 weeks 2.66+ 0.65 0.80+ 0.17 .011a
6 weeks 1.26+ 0.07 0.42+ 0.06 <.001a
12 weeks 1.40+ 0.12 0.4+ 0.04 <.001a
PCL Baseline 0.5+ 0.06 0.51+ 0.05 .65
3 weeks 2.18+ 0.40 1.06+ 0.2 .003a
6 weeks 1.51+ 0.07 0.52+ 0.06 <.001a
12 weeks 1.54+ 0.16 0.6+ 0.07 <.001a
Abbreviations: ACLT, anterior cruciate ligament transection; 3-D, 3-dimensional; 18F-FDG, 18F-fluoro-D-glucose; PCL, posterior cruciate ligament; SE, standard
error.
aP < .05 considered significant.
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in future studies to minimize staff radiotracer exposure and
logistics burden.
18F-fluoro-D-glucose uptake of the knee in an in vivo ACLT
canine model using PET- MRI coregistration demonstrated to
be highly sensitive in the detection of metabolic alterations in
different anatomical structures comprising the knee joint.
Hence, 18F-FDG uptake appears to be a potential imaging bio-
marker for an early OA diagnosis prior to the expression of
morphologic changes, as well as a diagnostic tool to assess OA
over time. In this study, we were able to prove our hypothesis
that ACLT knees presented with greater 18F-FDG uptake than
the uninjured knees.
This study combined innovative multimodal molecular ima-
ging techniques in a novel way to provide detailed,
comprehensive morphologic and metabolic information of the
knee in an ACLT canine model of OA. It also confirmed that
18F-FDG PET/CT coregistered with MRI can be used for serial
quantitative assessment of early OA metabolic changes in oss-
eous as well as nonosteochondral structures. The demonstrated
methodology increases our knowledge of OA mechanisms at
very early stages. The present findings highlight the impor-
tance of considering both molecular imaging and MRI to assess
knee disorders that initiate OA. Further work is warranted to
optimize the use of radiotracers in combination with MRI in
translational research to diagnose PTOA. Overall, this study
demonstrates the potential utility of FDG PET/CT combined
with MRI for clinical OA research and patient management and
is fully translatable to human applications.
Figure 4. Region of interest (ROIs) 18F-FDG SUVmax from the ACLT and uninjured knees at baseline, 3, 6, and 12 weeks. Data are expressed as
mean+ SEM. Different letters comparing ACLT ROIs across time (A, B, and C) differ significantly (P < .05). Asterisks (*) shows significant
difference between ACLT and uninjured knees. Posterior cruciate ligament (PCL). ACLT indicates anterior cruciate ligament transection;
18F-FDG, 18F-fluoro-D-glucose; SEM, standard error of the mean; SUVmax, maximum standardized uptake value.
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